

SEQUENCE LISTING

<110> Xie, Xiaoling
Gu, Yong
Markland, William
Su, Michael S.
Caron, Paul R.
Fox, Edward
Wilson, Keith P.
Vertex Pharmaceuticals, Inc.

<120> CRYSTALLIZABLE JNK COMPLEXES

<130> VPI/98-04 CON

<140>

<141>

<150> PCT/US99/09824, 60/084,056

<151> 1999-05-04, 1998-05-04

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 422

<212> PRT

<213> Homo sapiens

<220>

<223> JNK3

<400> 1

Met	Ser	Leu	His	Phe	Leu	Tyr	Tyr	Cys	Ser	Glu	Pro	Thr	Leu	Asp	Val
1				5					10					15	

Lys	Ile	Ala	Phe	Cys	Gln	Gly	Phe	Asp	Lys	Gln	Val	Asp	Val	Ser	Tyr
		20					25						30		

Ile	Ala	Lys	His	Tyr	Asn	Met	Ser	Lys	Ser	Lys	Val	Asp	Asn	Gln	Phe
		35					40					45			

Tyr	Ser	Val	Glu	Val	Gly	Asp	Ser	Thr	Phe	Thr	Val	Leu	Lys	Arg	Tyr
	50					55					60				

Gln	Asn	Leu	Lys	Pro	Ile	Gly	Ser	Gly	Ala	Gln	Gly	Ile	Val	Cys	Ala
	65				70					75					80

Ala	Tyr	Asp	Ala	Val	Leu	Asp	Arg	Asn	Val	Ala	Ile	Lys	Lys	Leu	Ser
			85						90					95	

Arg	Pro	Phe	Gln	Asn	Gln	Thr	His	Ala	Lys	Arg	Ala	Tyr	Arg	Glu	Leu
			100					105					110		

Val	Leu	Met	Lys	Cys	Val	Asn	His	Lys	Asn	Ile	Ile	Ser	Leu	Leu	Asn
		115					120					125			

Val	Phe	Thr	Pro	Gln	Lys	Thr	Leu	Glu	Glu	Phe	Gln	Asp	Val	Tyr	Leu
		130				135					140				

Val	Met	Glu	Leu	Met	Asp	Ala	Asn	Leu	Cys	Gln	Val	Ile	Gln	Met	Glu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

145	150	155	160
Leu Asp His Glu Arg Met Ser Tyr Leu Leu Tyr Gln Met Leu Cys Gly			
	165	170	175
Ile Lys His Leu His Ser Ala Gly Ile Ile His Arg Asp Leu Lys Pro			
	180	185	190
Ser Asn Ile Val Val Lys Ser Asp Cys Thr Leu Lys Ile Leu Asp Phe			
	195	200	205
Gly Leu Ala Arg Thr Ala Gly Thr Ser Phe Met Met Thr Pro Tyr Val			
	210	215	220
Val Thr Arg Tyr Tyr Arg Ala Pro Glu Val Ile Leu Gly Met Gly Tyr			
	225	230	235
Lys Glu Asn Val Asp Ile Trp Ser Val Gly Cys Ile Met Gly Glu Met			
	245	250	255
Val Arg His Lys Ile Leu Phe Pro Gly Arg Asp Tyr Ile Asp Gln Trp			
	260	265	270
Asn Lys Val Ile Glu Gln Leu Gly Thr Pro Cys Pro Glu Phe Met Lys			
	275	280	285
Lys Leu Gln Pro Thr Val Arg Asn Tyr Val Glu Asn Arg Pro Lys Tyr			
	290	295	300
Ala Gly Leu Thr Phe Pro Lys Leu Phe Pro Asp Ser Leu Phe Pro Ala			
	305	310	315
Asp Ser Glu His Asn Lys Leu Lys Ala Ser Gln Ala Arg Asp Leu Leu			
	325	330	335
Ser Lys Met Leu Val Ile Asp Pro Ala Lys Arg Ile Ser Val Asp Asp			
	340	345	350
Ala Leu Gln His Pro Tyr Ile Asn Val Trp Tyr Asp Pro Ala Glu Val			
	355	360	365
Glu Ala Pro Pro Pro Gln Ile Tyr Asp Lys Gln Leu Asp Glu Arg Glu			
	370	375	380
His Thr Ile Glu Glu Trp Lys Glu Leu Ile Tyr Lys Glu Val Met Asn			
	385	390	395
Ser Glu Glu Lys Thr Lys Asn Gly Val Val Lys Gly Gln Pro Ser Pro			
	405	410	415
Ser Ala Gln Val Gln Gln			
	420		

<210> 2
 <211> 39
 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Description of Artificial Sequence: primer

<400> 2
gctctagagc tccatgggca gcaaaagcaa agttgacaa

39

<210> 3
<211> 37
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 3
tagcggatcc tcattctgaa ttcattactt ccttgta

37

<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: glycine-rich
phosphate anchor loop

<220>

<223> Xaa throughout the sequence may be any amino acid

<400> 4
Gly Xaa Gly Xaa Gly Xaa Xaa
1 5

<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: glycine-rich
peptide

<400> 5
Gly Ser Gly Ala Gln Gly Ile Val
1 5

<210> 6
<211> 21
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EGF receptor
peptide

<400> 6
Lys Arg Glu Leu Val Glu Pro Leu Thr Pro Ser Gly Glu Ala Pro Asn
1 5 10 15

Gln Ala Leu Leu Arg
20